Editorial Office, Journal of Health and Medical Research, Belgium
Perspective
Treatment of Prolactinoma
Author(s): Ruth Paul*
Pituitary Neuroendocrine Tumors (PitNET) are most frequently prolactinomas, which account for around half of all such tumors. The bulk of prolactinomas has typically been treated with Dopamine Agonists (DAs), with surgery being the last resort. The goal is to examine the historical and contemporary management of prolactinomas, with a focus on the effectiveness, safety, and potential future directions of current therapeutic modalities. This includes medical therapy with DAs, trans-sphenoidal surgery, and multimodality therapy for the treatment of aggressive prolactinomas and metastatic PitNETs. Since the 1970s, DAs have been the cornerstone of prolactinoma therapy, first with bromocriptine and more recently with cabergoline. In up to 85% of patients, cabergoline normalizes prolactin, and in up to 80% of cases, it shrinks tumors. Similar to cabergoline, the primary surgical excision of .. View More»
DOI:
1037532.jhmr.2022.4.5.122
